SIGA Technologies (SIGA) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed SIGA Technologies (SIGA) over the past year, gaining 75.5% versus a loss of 61.4%. Over five years, SLGL leads with a -22.8% price change compared with -54.1% for SIGA. SIGA Technologies is the larger company by market cap ($226.7 million vs $225.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SIGA | SLGL |
|---|---|---|
| Share price | $3.16 | $68.93 |
| Market cap | $226.69M | $225.68M |
| 1-day change | -3.22% | -4.19% |
| YTD return | -46.64% | +70.73% |
| 1-year return | -61.37% | +75.52% |
| 5-year return | -54.15% | -22.85% |
| Forward P/E | 2.92 | — |
| EPS (TTM) | $-0.04 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.55 | $97.97 |
| 52-week low | $2.83 | $28.81 |
| Distance from 52-week high | -63.10% | -29.64% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +121.24% |
| Average volume | 726.50K | 55.30K |
| Shares outstanding | 71.85M | 3.27M |
| Employees | 49 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed SIGA by 136.9 percentage points over the past year.
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
SIGA vs SLGL FAQ
Which is bigger, SIGA Technologies or Sol-Gel Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $226.69M compared with $225.68M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, SIGA or SLGL?
SLGL returned +75.52% over the past 12 months, compared with -61.37% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are SIGA Technologies and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.